STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) IN POTENTIALLY OPERABLE STAGE I NON-SMALL CELL LUNG CANCER PATIENTS

被引：0
|
作者：
Lagerwaard, Frank J. [1 ]
Verstegen, Naomi E. [1 ]
Haasbeek, Cornelis J. [1 ]
Slotman, Ben [1 ]
Paul, M. A. [2 ]
Smit, Egbert F. [3 ]
Senan, Suresh [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Thorac Surg, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Stage I non-small cell lung cancer; Operable; Stereotactic ablative radiotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S278 / S279
页数：2
相关论文
共 50 条
  • [41] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Martel-Lafay, I.
    ONCOLOGIE, 2012, 14 (05) : 282 - 288
  • [42] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Slotman, Ben J.
    JOURNAL OF RADIOSURGERY AND SBRT, 2011, 1 (01): : 63 - 69
  • [43] Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.
    Schvartsman, Gustavo
    Pires de Rezende, Ana Carolina
    Diniz Gomes, Diogo Bugano
    Koch, Ludmila De Oliveira
    Bibas, Benoit Jacques
    Gomes, Oswaldo
    Campregher, Paulo V.
    Severino, Patricia
    Marti, Luciana Cavalheiro
    Paes, Vitor Ribeiro
    Chate, Rodrigo Caruso
    Ribas, Jose Milanez
    Ramos Sousa, Victor Aurelio
    Taranto, Patricia
    Moura, Fernando
    Terra, Ricardo Mingarini
    Samano, Marcos Naoyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Accelerated hypofractionated intensity modulated radiotherapy (IMRT) for early stage non-small cell lung cancer (NSCLC) in patients not suitable for conventional stereotactic ablative radiotherapy (SABR)
    Lavin, V.
    Whitehurst, P.
    Harris, C.
    Goldstraw, R.
    Bayman, N.
    Chan, C.
    Coote, J.
    Harris, M.
    Pemberton, L.
    Sheikh, H.
    Woolf, D.
    Faivre-Finn, C.
    LUNG CANCER, 2017, 103 : S53 - S54
  • [45] Is stereotactic ablative radiotherapy (SABR) a safe treatment for multiple primary lung cancer (MPLC) non-small cell lung cancer (NSCLC)?
    Murray, P. F.
    Spencer, K.
    Snee, M.
    Dickinson, P.
    Jain, P.
    Clarke, K.
    Franks, K.
    LUNG CANCER, 2016, 91 : S48 - S48
  • [46] Japanese Multicenter Study of Stereotactic Body Radiotherapy for 661 Medically Operable Patients with Stage I Non-Small Cell Lung Cancer
    Komiyama, Takafumi
    Onishi, Hiroshi
    Shioyama, Yoshiyuki
    Matsumoto, Yasuo
    Takayama, Kenji
    Matsuo, Yukinori
    Miyakawa, Akifumi
    Yamashita, Hideomi
    Nihei, Keiji
    Matsushita, Haruo
    Aoki, Masahiko
    Kimura, Tomoki
    Ishiyama, Hiromichi
    Murakami, Naoya
    Nakata, Kensei
    Takeda, Atsuya
    Uno, Takashi
    Nomiya, Takuma
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S210 - S211
  • [47] Dosimetric comparison of flattened and unflattened beams for stereotactic ablative radiotherapy of stage I non-small cell lung cancer
    Hrbacek, Jan
    Lang, Stephanie
    Graydon, Shaun N.
    Kloeck, Stephan
    Riesterer, Oliver
    MEDICAL PHYSICS, 2014, 41 (03)
  • [48] Stereotactic Ablative Radiotherapy in Clinical Stage I (< 5cm) Non-Small Cell Lung Cancer
    Ahn, S. J.
    Jeon, W.
    Kim, Y. C.
    Oh, I. J.
    Jeong, J. U.
    Yoon, M. S.
    Song, J. Y.
    Nam, T. K.
    Chung, W. K.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S655 - S656
  • [49] Measuring the Population Impact of Introducing Stereotactic Ablative Radiotherapy for Stage I Non-Small Cell Lung Cancer in Canada
    Louie, Alexander V.
    Rodrigues, George B.
    Palma, David A.
    Senan, Suresh
    ONCOLOGIST, 2014, 19 (08): : 880 - 885
  • [50] SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer
    Kwak, Yoo-Kang
    Park, Hee Hyun
    Choi, Kyu Hye
    Park, Eun Young
    Sung, Soo Yoon
    Lee, Sea-Won
    Hong, Ji Hyun
    Lee, Hyo Chun
    Yoo, Ie Ryung
    Kim, Yeon Sil
    CANCER RESEARCH AND TREATMENT, 2020, 52 (01): : 85 - 97
12345